Spark Therapeutics Target of Unusually Large Options Trading (ONCE)

Spark Therapeutics Inc (NASDAQ:ONCE) saw unusually large options trading activity on Tuesday. Stock traders purchased 3,782 call options on the stock. This is an increase of 2,582% compared to the average daily volume of 141 call options.

Spark Therapeutics (NASDAQ:ONCE) opened at $46.37 on Friday. Spark Therapeutics has a 52 week low of $41.06 and a 52 week high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.11). Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The business had revenue of $1.90 million during the quarter, compared to the consensus estimate of $1.40 million. During the same quarter in the previous year, the company earned ($1.07) earnings per share. The company’s revenue for the quarter was up 45.8% compared to the same quarter last year. sell-side analysts anticipate that Spark Therapeutics will post -7.6 EPS for the current fiscal year.

In related news, insider Daniel Faga sold 1,500 shares of the stock in a transaction that occurred on Tuesday, September 19th. The shares were sold at an average price of $85.00, for a total value of $127,500.00. Following the completion of the sale, the insider now directly owns 1,500 shares of the company’s stock, valued at approximately $127,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Katherine A. High sold 5,000 shares of the stock in a transaction that occurred on Tuesday, November 28th. The stock was sold at an average price of $71.32, for a total transaction of $356,600.00. Following the completion of the sale, the insider now directly owns 215,000 shares of the company’s stock, valued at $15,333,800. The disclosure for this sale can be found here. Insiders sold a total of 1,068,809 shares of company stock valued at $89,809,385 over the last three months. 7.30% of the stock is currently owned by insiders.

A number of hedge funds have recently bought and sold shares of ONCE. Teachers Advisors LLC boosted its position in shares of Spark Therapeutics by 1.9% during the 1st quarter. Teachers Advisors LLC now owns 34,534 shares of the biotechnology company’s stock valued at $1,842,000 after acquiring an additional 650 shares during the last quarter. Russell Investments Group Ltd. boosted its position in shares of Spark Therapeutics by 81.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 25,228 shares of the biotechnology company’s stock valued at $1,507,000 after acquiring an additional 11,335 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its position in shares of Spark Therapeutics by 8.2% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 94,920 shares of the biotechnology company’s stock valued at $5,671,000 after acquiring an additional 7,169 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new position in shares of Spark Therapeutics during the 2nd quarter valued at approximately $829,000. Finally, Rhumbline Advisers boosted its position in shares of Spark Therapeutics by 16.0% during the 2nd quarter. Rhumbline Advisers now owns 26,278 shares of the biotechnology company’s stock valued at $1,570,000 after acquiring an additional 3,626 shares during the last quarter. Institutional investors and hedge funds own 94.94% of the company’s stock.

Several research firms recently issued reports on ONCE. Goldman Sachs Group reissued a “buy” rating and issued a $111.00 target price on shares of Spark Therapeutics in a report on Friday, October 6th. BMO Capital Markets set a $89.00 target price on shares of Spark Therapeutics and gave the stock a “buy” rating in a report on Tuesday, October 10th. Cowen reissued a “buy” rating and issued a $95.00 target price on shares of Spark Therapeutics in a report on Tuesday, October 10th. Chardan Capital reissued a “buy” rating and issued a $100.00 target price on shares of Spark Therapeutics in a report on Friday, October 13th. Finally, Raymond James Financial began coverage on shares of Spark Therapeutics in a report on Thursday, October 12th. They issued an “outperform” rating and a $96.00 target price for the company. Two analysts have rated the stock with a sell rating, five have issued a hold rating and fifteen have given a buy rating to the stock. Spark Therapeutics has a consensus rating of “Buy” and a consensus price target of $76.19.

WARNING: “Spark Therapeutics Target of Unusually Large Options Trading (ONCE)” was originally posted by Week Herald and is the property of of Week Herald. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://weekherald.com/2017/12/17/spark-therapeutics-target-of-unusually-large-options-trading-once.html.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply